https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / Technol. Cancer Res. Treat. 2014 Apr;13(2):169-752013-06-24 00:00:002013-06-24 00:00:00Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-24 / J. Clin. Invest. 2013 Jul;123(7):3135-452013-06-24 00:00:002019-02-15 08:48:46Melanoma immunotherapy using mature DCs expressing the constitutive proteasome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-21 / Cancer Treat. Rev. 2013 Dec;39(8):891-907
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-21 / Cancer Treat. Rev. 2013 Dec;39(8):891-9072013-06-21 00:00:002019-02-15 08:46:27Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-19 / Antioxid. Redox Signal. 2013 Dec;19(17):2141-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-19 / Antioxid. Redox Signal. 2013 Dec;19(17):2141-562013-06-19 00:00:002013-06-19 00:00:00Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-18 / J Transl Med 2013 Jun;11:149
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-18 / J Transl Med 2013 Jun;11:1492013-06-18 00:00:002019-02-15 08:52:12A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-04 / J Clin Oncol 31, 2013 (suppl; abstr e20042)2013-06-04 11:44:592019-07-17 11:45:20Biochemical and immunologic markers in patients with metastatic melanoma treated with chemotherapy and dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-04 / Oncol Lett 2013 Aug;6(2):537-541
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-04 / Oncol Lett 2013 Aug;6(2):537-5412013-06-04 00:00:002019-02-15 08:39:47Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3040)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3040)2013-06-03 11:37:322019-07-17 11:38:06Effect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3100)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 3100)2013-06-03 00:00:002013-06-03 00:00:00Role of mesenchymal stem cells in delivering Newcastle disease virus to glioma cells and glioma stem cells and enhancing the oncolytic effect of the virus by secreting TRAIL.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 10013)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-06-03 / J Clin Oncol 31, 2013 (suppl; abstr 10013)2013-06-03 00:00:002021-08-09 07:55:21Survival in metastatic Ewing sarcoma (EWS) and rhabdomyosarcoma (RMS) following consolidation immunotherapy with autologous lymphocyte infusion, dendritic cell vaccines ± CYT107 (rhIL-7).
